Benzinga

Benzinga

Benzinga

sábado, agosto 29

Novo Nordisk AS

NVONYSE
Trade with Public
Trade with Public
$45.61
-0.65-1.41%
al cierre: Aug 28, 5:00 PM EST
$45.60
-0.01-0.02%
After hour: 7:59 PM EST
Panorámica generalNoticiasPrevisión de beneficiosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Novo Nordisk Analyst Price Targets

Wall Street analyst price targets and consensus rating for Novo Nordisk (NVO).

Price Target Range — 9 Quarters

Analyst Consensus — 12 Analysts

4Buy
6Hold
2Sell
Consensus RatingOverweight# Analysts12Avg. Consensus PT$85Upside to Avg. PT+87.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Mar 2, 2026Goldman SachsJames QuigleyDowngradeBuy→Neutral$63→$41
Feb 24, 2026JP MorganRichard VosserDowngradeOverweight→Neutral—
More with Benzinga EdgeGet Access

Analyst Ratings News

Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst

HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $42. Company's revenue up 38.2% YoY.
Priya Nigam

Why Is BioAge Labs Stock Sinking Friday?

BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
Vandana Singh

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts

Hims & Hers Health shares tank after disappointing Q1 results. Company raised 2026 revenue outlook. EBITDA outlook was lowered by $25M.
Priya Nigam

March Inflation Set For Biggest Jump Since June 2022 — When CPI Spikes, These Stocks Fall

Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9% monthly CPI surge — the steepest since June 2022.
Piero Cingari

Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations

HSBC downgrades Eli Lilly to reduce, citing pricing pressure, rising competition, and overestimated obesity drug market growth expectations.
Vandana Singh

Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook

Korro Bio stock rises after earnings as analysts upgrade outlook, highlight new drug candidate, and long-term growth plans.
Vandana Singh

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved